PBYI

PBYI has quietly transformed from a cash-burning story into a genuinely profitable one: FY2025 net income of $31.1M (+2.8% YoY) on operating income of $37.3M (+20.5%), a 16.3% operating margin, 13.6% net margin, and a striking 23.9% ROE. The balance sheet is clean — long-term debt was retired to $0 (from a year ago), liabilities/equity sits at just 0.66x, and equity grew 41.5% to $130M. Operating cash flow of $41.8M against essentially zero capex ($71K) makes this a real cash machine. At $8.26 the stock trades at 13.5x earnings and 1.8x sales, which is undemanding for a company earning a mid-20s return on equity. On the numbers alone, this looks like value.

The problem is what the numbers don't do: grow. Revenue has drifted down every relevant year — $253M (2021) → $228M (2025), -0.9% in the latest year — because, as the 10-K states plainly, PBYI is 'a single product company' whose 'success depends entirely on the commercial success of NERLYNX.' The margin and net-income gains have come from cost discipline and debt paydown, not from a growing franchise. That is a finite lever. NERLYNX is a mature, HER2-breast-cancer product facing the usual erosion pressures, and there is no organic top-line engine behind it. A company that can't grow revenue is worth a low multiple — and the market is already paying roughly that.